Cel Sci Corporation (CVM)

[GD]

I have been in biotech investing for 30 years, and you
think I do not know BLA applications, LOL. My post to
you is let's see MK pass the primary OS endpoint first,
everything else is second important, when the data base
is locked, the trial fate is sealed for ever, you can
analysis the data down to each patient will not change
the picture of: is the trial primary OS endpoint P value
less than 0.05 or not.